Added 22 days ago Drug news
Update on forthcoming CHMP decision for betrixaban as a treatment for venous thromboembolism.- Portola Pharma
Portola Pharmaceuticals Inc.'s Factor Xa inhibitor betrixaban's future in the EU is looking uncertain after the EMA's CHMP issued a...
Added 2 months ago Drug news
Ubenimex fails in LIBERTY study for pulmonary arterial hypertension and is discontinued for this condition.
Eiger BioPharmaceuticals, Inc. focused on the development and commercialization of targeted therapies for rare diseases, announced Phase II LIBERTY study...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.
Watch video highlights from the BeCOn OWN 2017 event, including expert opinion, patient experience and panel discussions in the Breakthrough Cancer Pain Learning Zone.
View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more.
Explore the pathophysiology and treatment options for Fabry disease, a deficiency of the lysosomal enzyme alpha-galactosidase A
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
Venous thromboembolism (VTE) and bleeding are serious complications of cancer and its treatment. A recent survey of UK paediatric haematologists and oncologists identified a broad variety of practice in the management of issues...
Added 3 days ago
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and can complicate the majority of cardiovascular...
Added 2 years ago
This guideline reviews the indication for warfarin, duration or treatment for patients with a PE and/or lower limb DVT, the initiation of treatment, the management of peri-operative anticoagulation, the management of patients who are bleeding or...
Added 2 years ago
Rivaroxaban vs Warfarin and Risk of Post-Thrombotic Syndrome among Patients with Venous Thromboembolism.
The effectiveness of rivaroxaban to reduce post-thrombotic syndrome in patients with venous thromboembolism is largely unknown. We compared rates of post-thrombotic syndrome in patients given rivaroxaban versus warfarin...
Added 5 days ago
Clinical trials and meta-analyses have suggested that aspirin may be effective for the prevention of venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism) after total hip or total knee arthroplasty, but comparisons...
Added 11 days ago
Background: Although many patients with venous thromboembolism require extended treatment, it is uncertain whether it is better to use full- or lower-intensity anticoagulation therapy or aspirin.
Added 5 months ago
A Study to Investigate Different Doses of BAY1213790 to Prevent Blood Clots in Patients Undergoing Elective Total Knee Replacement Surgery (FOXTROT)
This study is to compare the study drug BAY1213790 to existing therapies, ie Enoxaparin or Apixaban for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).
Added 4 months ago
Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) (EinsteinChoice)
This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy.
Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism)...
Added 5 years ago
Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty (EPCAT II)
In this study the investigators want to look at whether using aspirin instead of rivaroxaban (after initial treatment with rivaroxaban) works as well at preventing blood clots while also reducing risk of bleeding...
Added 11 days ago
Dr David R Warriner is currently a Cardiology Registrar practising in South Yorkshire. Dr Warriner's clinical and research interests include heart failure, exercise physiology, physiological modelling, sports medicine and medical education. In his free time, Dr Warriner loves reading ... Read more
Overdiagnosis is the diagnosis of disease that will cause neither morbidity nor mortality during a patient’s lifetime. Doctors are trained to listen, examine, test, diagnose and treat patients, but we are not warned of the possible dangers of “diseases”, the diagnosis of which will not benefit the patient and may also lead to harm. I would argue that the Hippocratic oath, in particular “Primum non nocere” (first, do no harm) should be at the forefront of every clinician’s mind when seeing patients.